Analysis Tools
hematopoietic system
|
• when cells from a mouse treated with pIpC at 6 to 12 weeks where exposed to IL-7 in a clonogenic assay, the number and size of pre-B cell colonies is reduced compared to in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, the progenitor compartment is enlarged and the number of hematopoietic stem cells is increased compared to in wild-type mice
|
|
• when cells from a mouse treated with pIpC at 6 to 12 weeks where exposed to IL-7 in a clonogenic assay, the number of myeloid colony forming units is increased 2-fold, all types of myeloid-derives cells are present at a 6-fold higher level, and granulo-mono-erythromegakaryocitic colonies are denser and contain a 5-fold increase in primitive common myeloid progenitors relative to in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, the total number of bone marrow cells is nearly one third less than in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit decreased erythrocyte numbers compared to in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, some mice are thrombocytotic
|
|
• following treatment with pIpC at 6 to 12 weeks, the number of lymphoid B cells is slightly decreased compared to in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit decreased splenocyte numbers compared to in wild-type mice
|
immune system
|
• when cells from a mouse treated with pIpC at 6 to 12 weeks where exposed to IL-7 in a clonogenic assay, the number and size of pre-B cell colonies is reduced compared to in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, the number of lymphoid B cells is slightly decreased compared to in wild-type mice
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit decreased splenocyte numbers compared to in wild-type mice
|
